Key Indian panel favors waiving-off local Phase III trials for drugs approved abroad
This article was originally published in SRA
A key Indian advisory panel has issued recommendations to facilitate the faster registration of drugs that are already approved in other countries by removing the need to conduct local Phase III trials in certain circumstances1.
You may also be interested in...
A new draft guideline explains how sponsors of subsequent-entry orally inhaled drug products can comply with the Canadian requirement for demonstrating equivalence to the reference product.
While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.
Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”